might interest some....Bristol Myers beats estimates with new drug sales surge
Bristol Myers Squibb ($BMY) outperformed in Q4 with adjusted earnings per share of $1.70 (compared to the expected $1.53) and revenue of $11.48B (surpassing the expected $11.19B). The sales boost was driven by higher sales of new drugs, including Reblozyl and Opdualag, contributing $1.07B, up 66% from the previous year.
fwiw...Opdualag had sales of $190M for 4th qtr of 2023, contrast this with sales of $45M for 3rd qtr 2022..
Media, page-617
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.3¢ |
Change
0.003(0.74%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.8¢ | 33.5¢ | $620.3K | 1.818M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 112407 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 207961 | 38 |
View Market Depth
| Last trade - 15.48pm 26/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |